Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18
Benzinga Newsdesk 7 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.
Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.